Why England's 'Life-Changing' MS Drug Took 16 Years

For someone living with multiple sclerosis, every trip out of the front door starts as a calculation about whether the energy cost of the walk is worth whatever waits at the other end. Fatigue, foot drop, and unreliable balance turn a short journey to the shops into an event that has to be scheduled, budgeted, and recovered from. Walking is the most ordinary thing a body does, which is exactly why losing it quietly rearranges an entire life.

That friction is the backdrop to the story dominating life coverage this week. NHS England has confirmed that fampridine, the first medicine designed specifically to improve walking in adults with multiple sclerosis, is now routinely available, with thousands of patients expected to begin treatment in the first year. The drug acts like a signal booster, helping damaged nerves carry messages more reliably, and it is taken as a pill twice a day. The rollout was described as life-changing, and for the people it works for, that description is honest, as BBC News reported when the drug became available.

But the rollout deserves more scrutiny than the celebration allowed. The drug is not new, and it is not a cure. For roughly half the people who try it, it produces no measurable benefit. The gap between the headline and the mechanism is the real story, and it starts with what the drug actually does.

A Signal Booster, Not a Cure

Fampridine works on symptoms, not on the disease itself. Multiple sclerosis damages the myelin sheath that insulates nerve fibres, which slows or blocks the electrical signals that control movement. Fampridine, a potassium channel blocker, helps those damaged fibres conduct signals again, which is why NHS England's own material describes it as a signal booster. It does not repair myelin, slow the accumulation of disability, or reduce relapses. It is a symptomatic treatment, the first one aimed squarely at walking.

That distinction matters because it sets expectations. A disease-modifying therapy changes the course of MS over years, while fampridine changes what a Tuesday afternoon feels like. Both matter, but they are different promises, and confusing them is how disappointment gets manufactured. The drug's targets are precise: adults with MS whose walking is impaired but who still have some mobility, typically assessed on the Expanded Disability Status Scale. In trials, the gains show up as walking speed for the people who respond.

That sounds modest on paper. In a life, it can be the difference between crossing a road before the light changes and waiting for someone to come and help. It can be the difference between taking a job that involves a commute and staying home. The size of the clinical effect is not the same as the size of the effect on a day.

The Half Who Walk Away

The number the headlines tended to skip is the response rate. Clinical trials have shown that roughly 43 percent of people who take fampridine experience a measurable improvement in walking speed, and patient organisations put the figure closer to one in two. Either way, a substantial share of the people who start the drug will not see a benefit. The protocol is built around that reality: treatment begins with a trial period, typically two weeks, and anyone who does not show a clear improvement stops.

That design is the most honest part of the whole rollout. It treats the drug as what it is, a test with an exit plan, rather than a prescription to be accumulated. It also means the thousands of patients in the NHS announcement is not a count of people who will walk better. It is a count of people who will get the chance to find out, and about half of them will be told the drug is not for them.

Do the arithmetic and the scale of the announcement comes into focus. If roughly five thousand people start fampridine in the first year, and the response rate holds at around 45 percent, the number who keep taking it is closer to two thousand. That is still a significant group of people walking better, crossing roads unaided, staying in work longer. It is just not the group the headlines implied, and knowing the difference matters for anyone waiting to be referred.

There are also real safety constraints. Fampridine lowers the seizure threshold, and the risk appears higher than earlier estimates suggested, which is why it is not offered to people with a history of seizures or significant kidney problems. The monitoring is straightforward, but it is monitoring, and it is part of the reason this drug took so long to reach routine use. None of this makes the rollout less valuable. It makes it less simple, which is the point.

Sixteen Years Between Approval and Access

The uncomfortable fact is that fampridine is not a breakthrough in any scientific sense. It was approved in the United States in 2010. Within the UK, Wales began funding it in 2019, Scotland in 2020, and Northern Ireland in 2023. England, which covers the largest population, announced its recommendation only last month, and the timing was not driven by new evidence about how well the drug works. It was driven by the patent expiring and generic versions becoming available at a price the health service could accept.

That sequence is worth sitting with. The same medicine, the same trials, the same safety profile, was considered fundable in Cardiff in 2019 and not in England for another seven years. The drug did not change. The price did. Quality of life for people with MS had a number attached to it, and it took a generic market to bring that number down.

The gap was not for lack of campaigning. MS charities in England had pushed for access for years, pointing at the evidence from the rest of the UK and arguing that walking impairment was being treated as a lesser priority than relapse prevention. The recommendation finally arrived alongside the generic market, a sequence that reads less like a scientific verdict and more like an accounting one. Access decisions are always partly about price. This one was mostly about price, and it is worth saying plainly because it changes what the story means.

The delay matters because walking is not a cosmetic concern. Mobility loss is one of the strongest predictors of social isolation, loss of employment, and deteriorating mental health for people with MS. Every year of delay is a year of lives organised around a calculation at the front door. The rollout is genuinely good news, and it is also a case study in how health systems value the quality of a life compared with the length of it.

What the Delay Really Says

The deeper lesson is about how progress gets framed. When a health system finally funds a symptom drug after a sixteen-year wait, it is tempting to report the story as medical innovation. It is more accurate to report it as an access story, and access stories are about priorities, not science. The same pattern shows up in wellness culture, where the detox that doesn't rebound is the one built on honest measurement rather than hype.

For anyone with MS, or caring for someone who has it, the practical read is simpler. If walking speed is the bottleneck in a life, a fampridine trial is worth having with a neurologist, because the two-week test will answer the question quickly and honestly. The pill should not be mistaken for the whole strategy. The unglamorous work, physiotherapy, strength training, and environments designed to be accessible, still carries most of the load, and it always has.

The test of this rollout will not be how many headlines it generated in August. It will be how many people, a year from now, are still crossing roads on their own. For the people inside that number, the drug will be exactly as life-changing as the announcement promised. For everyone else, living with MS continues the way it always has, one calculated trip out the front door at a time, and that work deserves the same respect the headlines gave the pill.